Actinium Pharmaceuticals (Delaware) (ATNM) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NanoViricides (NNVC) has outperformed Actinium Pharmaceuticals (Delaware) (ATNM) over the past year, losing 8.4% versus a loss of 26.7%. Over five years, NNVC leads with a -73.2% price change compared with -86.3% for ATNM. Actinium Pharmaceuticals (Delaware) is the larger company by market cap ($34.6 million vs $33.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | NNVC |
|---|---|---|
| Share price | $1.10 | $1.30 |
| Market cap | $34.59M | $33.18M |
| 1-day change | +1.85% | -0.76% |
| YTD return | -19.12% | +15.93% |
| 1-year return | -26.67% | -8.39% |
| 5-year return | -86.32% | -73.16% |
| P/E ratio (TTM) | 3.06 | — |
| EPS (TTM) | $0.36 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $2.23 |
| 52-week low | $0.735 | $0.85 |
| Distance from 52-week high | -36.78% | -41.70% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +227.27% | +361.54% |
| Average volume | 139.78K | 445.00K |
| Shares outstanding | 31.44M | 25.52M |
| Employees | 27 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed ATNM by 18.3 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ATNM vs NNVC FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or NanoViricides?
Actinium Pharmaceuticals (Delaware) (ATNM) is larger, with a market capitalization of $34.59M compared with $33.18M for NanoViricides (NNVC).
Which stock has performed better over the past year, ATNM or NNVC?
NNVC returned -8.39% over the past 12 months, compared with -26.67% for ATNM (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and NanoViricides in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.